Six red flags for suspect work (original) (raw)

• Comment
• Published: 22 May 2013

Reproducibility

Nature volume 497, pages 433–434 (2013)Cite this article

• 35k Accesses
• 195 Citations
• 168 Altmetric
• Metrics details

Subjects

C. Glenn Begley explains how to recognize the preclinical papers in which the data won't stand up.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

• PyPads

  • Thomas Weißgerber
  • , Mehdi Ben Amor
  • … Michael Granitzer
    Datenbank-Spektrum Open Access 28 November 2023

• Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology

  • Marcus Baaz
  • , Tim Cardilin
  • … Mats Jirstrand
    BMC Cancer Open Access 06 May 2023

• Should We Strive to Make Science Bias-Free? A Philosophical Assessment of the Reproducibility Crisis

  • Robert Hudson
    Journal for General Philosophy of Science Open Access 22 April 2021

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

References

1. Prinz, F., Schlange, T. & Asadullah, K. Nature Rev. Drug Discov. 10, 712 (2011).
   Article CAS Google Scholar
2. Begley, C. G. & Ellis, L. M. Nature 483, 531–533 (2012).
   Article ADS CAS Google Scholar
3. Rossner, M. 'How to Guard Against Image Fraud' The Scientist (1 March 2006); available at http://go.nature.com/bjjbe4
   Google Scholar
4. Vaux, D. L. Nature 492, 180–181 (2012).
   Article ADS CAS Google Scholar

Download references

Author information

Authors and Affiliations

1. C. Glenn Begley is senior vice-president at TetraLogic Pharmaceuticals, Malvern, Pennsylvania, USA.,
   C. Glenn Begley

Corresponding author

Correspondence toC. Glenn Begley.

Ethics declarations

Competing interests

C.G.B. is on the board of directors of Oxford Biotherapeutics and on the scientific advisory board of several companies. He holds stock in Amgen.

Related links

Rights and permissions

About this article

Cite this article

Begley, C. Six red flags for suspect work.Nature 497, 433–434 (2013). https://doi.org/10.1038/497433a

Download citation

• Published: 22 May 2013
• Issue date: 23 May 2013
• DOI: https://doi.org/10.1038/497433a

This article is cited by

Comments

Commenting on this article is now closed.

1. Nitin Gandhi 23 May 2013, 22:41
   Now that the six red flags are out &#8211 researchers will "take care" of these while "writing" a paper!